- 现金
- 4865 元
- 精华
- 4
- 帖子
- 1027
- 注册时间
- 2004-11-2
- 最后登录
- 2020-4-2
|
1楼
发表于 2004-11-20 09:57
文题:Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.
作者:Fung SK, Wong F, Hussain M, Lok AS
杂志全名:Journal of Viral Hepatitis
年份,卷(期): 起止页码:2004 ;11(5):432-8
PMID: 15357648
英文摘要:
Lamivudine has demonstrated efficacy for the treatment of hepatitis B e antigen-negative chronic hepatitis B (e-CHB ). However, treatment withdrawal after 1 year has been associated with a high rate of relapse while long-term treatment is associated with increasing risks of drug resistance. We report our treatment experience of 50 Chinese-Canadian patients with e-CHB. All patients received lamivudine for 2 years. Treatment was withdrawn at month 24 in patients who had undetectable hepatitis B virus (HBV) DNA by PCR and normal aminotransferases during the second year of therapy. All patients had HBV genotype B or C. Biochemical response at months 6, 12 and 24 was 74%, 71% and 66%, respectively. HBV DNA was undetectable at months 6, 12 and 24 by hybrid capture and PCR assays in 100%, 92% and 86%; and 94%, 88% and 74% patients, respectively. The cumulative rates of genotypic resistance (GR) after 1 and 2 years were 15% and 25%, respectively. Four (44%) patients with GR experienced a hepatitis flare. The probability of clinical and virological relapse 6, 12, and 18 months after treatment withdrawal were 12% and 30%, 18% and 50%, and 30% and 50%, respectively. Reinstitution of lamivudine resulted in prompt virological and biochemical responses. Our study demonstrates that a sustained response can be achieved after a 2-year course of lamivudine in a subset of patients with e-CHB.
中文译文:
2年拉米夫定治疗HBeAg阴性慢性乙型肝炎的持续应答
[摘要]
背景与目的;
拉米夫定可有效的治疗HBeAg阴性慢性乙型肝炎(e-CHB ),但在治疗1年后停药复发率高而长期治疗又增长了耐药风险。
方法;
我们报道50例华裔加拿大e-CHB患者的治疗经验,全部患者接受2年的拉米夫定治疗,在第二年期间患者使用PCR方法HBV DNA水平无法检测及转氨酶正常时在24个月停药.
结果;
全部患者HBV基因型为B或C型,生化应答在6,12,24个月分别为74%, 71% 与66%,在6,12,24个月使用杂交捕获试验与PCR方法检测,HBV DNA水平无法检测率分别为100%, 92% ,86%与94%, 88% ,74%.在1年与2年后累积基因型抵抗(GR)率分别为15%与25%,4例(44%)GR患者有肝炎发作,在治疗停止后6,12,18个月临床与病毒学复发可能性分别为12% 与30%, 18% 与 50%,30% 与 50%,再次拉米夫定治疗后可有迅速的病毒学与生化应答.
结论;
我们的研究证实HBeAg阴性慢性乙型肝炎患者2年拉米夫定治疗可获得持续的应答。 |
|